MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00784-026-06996-4

Медицинская библиотека · Clinical oral investigations · 2026

Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study.

Kim Jaeyeon, Choi Eun-Jeong, Kim Jun-Young, Choi Yiseul, Park Wonse

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

To characterize invasive dental procedures in romosozumab-treated osteoporosis patients and describe medication-related osteonecrosis of the jaw (MRONJ) according to exposure timing.

METHODS

This retrospective study used electronic medical records and prescription/administration data from Yonsei University Dental Hospital between 2019 and 2024. Participants who received romosozumab, underwent tooth extraction and/or implant placement, and had at least 6 months of follow-up were included. Invasive dental procedures were categorized according to the timing of romosozumab administration relative to dental treatment (before, after, or both before and after treatment). MRONJ was identified according to American Association of Oral and Maxillofacial Surgeons criteria. Analyses were descriptive.

RESULTS

A total of 201 participants underwent 303 invasive procedures (231 extractions, 72 implants). Extractions were most commonly performed for retained root (30.3%), caries (22.1%), periodontal disease (19.0%), and fractures (11.7%). Among the procedures, 77 (25.4%) were categorized as before dental treatment, 182 (60.1%) as after dental treatment, and 44 (14.5%) as before and after dental treatment relative to romosozumab administration. One case of MRONJ occurred in a participant with sequential exposure to denosumab, romosozumab, and subsequent intravenous zoledronic acid therapy, accompanied by local infection.

CONCLUSIONS

A causal relationship with romosozumab monotherapy could not be determined because MRONJ occurred during cumulative and sequential antiresorptive exposure with local infection. Larger studies are needed to assess risks related to treatment sequence and cumulative exposure.

CLINICAL RELEVANCE: Clinicians managing patients receiving romosozumab should consider cumulative antiresorptive exposure, local infection, and close coordination between physicians and dentists.

Для цитирования: Kim Jaeyeon, Choi Eun-Jeong, Kim Jun-Young, Choi Yiseul, Park Wonse. Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study.. Clinical oral investigations. 2026. DOI: 10.1007/s00784-026-06996-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.